WallStreetZenWallStreetZen

NYSE: CRL
Charles River Laboratories International Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for CRL

Based on 9 analysts offering 12 month price targets for Charles River Laboratories International Inc.
Min Forecast
$205.00+4.01%
Avg Forecast
$233.89+18.67%
Max Forecast
$275.00+39.52%

Should I buy or sell CRL stock?

Based on 9 analysts offering ratings for Charles River Laboratories International Inc.
Strong Buy
Strong Buy
5 analysts 55.56%
Buy
1 analysts 11.11%
Hold
3 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CRL stock forecasts and price targets.

CRL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-10
lockedlocked$00.00+00.00%2023-11-09
lockedlocked$00.00+00.00%2023-09-25
lockedlocked$00.00+00.00%2023-09-22
lockedlocked$00.00+00.00%2023-09-22
Wells Fargo
Bottom 18%
18
Strong BuyMaintains$275.00+40.87%2023-09-22
JP Morgan
Top 15%
86
Strong BuyMaintains$250.00+28.06%2023-08-10
Bank of America
Top 8%
93
Strong BuyMaintains$245.00+25.50%2023-08-10
Citigroup
Top 11%
90
HoldDowngrades$225.00+15.25%2023-07-11

1 of 1

Forecast return on equity

Is CRL forecast to generate an efficient return?
Company
N/A
Industry
0.13%
Market
30.3%

Forecast return on assets

Is CRL forecast to generate an efficient return on assets?
Company
N/A
Industry
0.09%

CRL revenue forecast

What is CRL's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$4.1B-2.69%
Avg 2 year Forecast
$4.3B+1.05%
Avg 3 year Forecast
$4.6B+9.68%
CRL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRL earnings growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
20.36%
Industry
24.12%
Market
17.93%
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

CRL revenue growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
2.83%
Industry
4.94%
Market
7.56%
CRL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRL vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
CRL$195.22$233.89+19.81%Strong Buy
QGEN$41.12$50.50+22.81%Strong Buy
RVTY$87.75$118.71+35.29%Buy
MEDP$270.58$281.00+3.85%Strong Buy
EXAS$64.97$100.00+53.92%Strong Buy
View Top Diagnostic & Research Stocks

Charles River Laboratories International Stock Forecast FAQ

Is Charles River Laboratories International Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NYSE: CRL) stock is to Strong Buy CRL stock.

Out of 9 analysts, 5 (55.56%) are recommending CRL as a Strong Buy, 1 (11.11%) are recommending CRL as a Buy, 3 (33.33%) are recommending CRL as a Hold, 0 (0%) are recommending CRL as a Sell, and 0 (0%) are recommending CRL as a Strong Sell.

If you're new to stock investing, here's how to buy Charles River Laboratories International stock.

What is CRL's revenue growth forecast for 2023-2025?

(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 2.83% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.56%.

Charles River Laboratories International's revenue in 2023 is $4,215,776,000.On average, 6 Wall Street analysts forecast CRL's revenue for 2023 to be $210,431,749,944, with the lowest CRL revenue forecast at $209,945,251,055, and the highest CRL revenue forecast at $210,845,766,449. On average, 6 Wall Street analysts forecast CRL's revenue for 2024 to be $218,524,282,446, with the lowest CRL revenue forecast at $216,567,668,451, and the highest CRL revenue forecast at $221,150,781,405.

In 2025, CRL is forecast to generate $237,180,314,500 in revenue, with the lowest revenue forecast at $234,384,689,978 and the highest revenue forecast at $240,053,653,679.

What is CRL's forecast return on assets (ROA) for 2023-2026?

(NYSE: CRL) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of 0.09%.

What is CRL's Price Target?

According to 9 Wall Street analysts that have issued a 1 year CRL price target, the average CRL price target is $233.89, with the highest CRL stock price forecast at $275.00 and the lowest CRL stock price forecast at $205.00.

On average, Wall Street analysts predict that Charles River Laboratories International's share price could reach $233.89 by Nov 10, 2024. The average Charles River Laboratories International stock price prediction forecasts a potential upside of 19.81% from the current CRL share price of $195.22.

What is CRL's forecast return on equity (ROE) for 2023-2026?

(NYSE: CRL) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.